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Correspondence 
Hydrostatic Systolic Toe Pressure for Diagnosis 
of Peripheral Ischaemic Vessel Disease in 
Diabetes Mellitus 
Sir, 
Recently Smith et al. have introduced a new non- 
invasive method, the hydrostatic method or 'pole test', 
for measuring the true blood pressure in the lower 
l imb) In an artery with a non-compliant wall, hydro- 
static blood pressure is represented by the height of 
elevation above heart level, at which the blood flow 
ceases in this artery. Diabetic patients most frequently 
have non-compliant arteries. 2'3 Therefore, we have 
applied this technique to measure systolic ankle 
pressure in 142 diabetic legs of 75 patients (mean(s.D.) 
age 62(10) years, duration of diabetes 21(11)years; 
evidence of polyneuropathy (n = 67 patients), diabetic 
kidney disease (n = 44), and diabetic eye disease 
(n = 50)). In 72 legs, medial arterial calcification 
(MAC) was present on X-ray. In 6i legs, there was 
angiographic evidence of peripheral ischaemic vessel 
disease (PIVD), and in 31 legs there was both, MAC 
and PIVD. Using conventional Doppler and sphygmo- 
manometr~ the systolic ankle/brachial pressure index 
(ABPI) was < 0.9 in 61 legs, and > 0.9 in 81 legs. 
Systolic hydrostatic ankle pressure was measured 
according to Smith et aI.1; however, 100% of readings 
in legs with ABPI > 0.9, and 73% of readings in legs 
with ABPI < 0.9 were beyond the upper detection 
limit of approx. 60mm Hg)  Thus, the pole test 
conveys little benefit for arterial pressure measure- 
ment at the ankle level in diabetes mellitus. However, 
when used to measure the toe arterial pressure, the 
utility of this method could improve substantially for 
two reasons. Firstly, the systolic pressure in the toe 
arteries is approx. 50 mm Hg less than in the ankle 
arteries 4 and, hence, a greater number of readings will 
fall within the range of measurement. Secondl~ the 
big toe is approx. 20 cm distal to the ankle and can be 
elevated above the heart level higher than the ankle 
thereby extending the range of measurements from 
Table 1. Site of systolic pressure measurement 
Ankle Ankle Big toe 
Method sphygmo- hydrostatic hydrostatic 
manometry 
Range of 
measurement 0-300 mm Hg* 0qS0 mm Hg 0-70 mm Hg 
% readings 
beyond upper 
range 22%* 80% 38% 
*Including fallacious readings in patients with MAC. ], 3, 5 
60 mm Hg to 70 mm Hg. Table 1 shows the feasibility 
of the hydrostatic pole test for measuring the systolic 
ankle and toe pressure in 45 diabetic legs. 
According to these results, we suggest that in 
diabetic patients the ankle arterial pressure measure- 
ment by conventional sphygomanometry should be 
abandoned, because it frequently yields fallacious 
results due to MAC. 1-3's With the pole test, most ankle 
pressure readings fall outside the range of measure- 
ment. We suggest herefore, that both these proce- 
dures be replaced by the hydrostatic toe pressure 
measurement for diagnosing PIVD in diabetes melli- 
tus. True pressure values from 0 to 70 mm Hg can be 
obtained by this method, and all of the readings can be 
interpreted unequivocally. A systolic arterial pressure 
in the big toe > 45 mm Hg is indicative of sufficient 
arterial blood flow, irrespective of diabetes4; systolic 
toe pressure> 70ram Hg (i.e. beyond the upper 
detection limit of the hydrostatic method) can safely 
be regarded as normal. 
E. Chantelau and H.W. Sambraus 
D~sseldorf, Germany 
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Editor's Comment 
A reply to this letter was requested from the authors 
but not received. The pole test, as described by Smith 
et aI. only designed for use in diabetes with suspected 
critical limb ischaemia. In these patients, a persistent 
signal at the ankle despite full elevation of the leg 
means that perfusion is usually adequate. However, 
the suggestion of using toe pressures eems a good 
one provided a sufficiently sensitive Doppler probe is 
used. 
Pulse Spray Thrombolysis 
Sir, 
We would like to comment on the paper by Yusuf et al. 
(Eur I Vasc Endovasc Surg 1995; 10:136-141). This paper 
sets out to prove that pulse spray thrombotysis i  
quicker than conventional low-dose infusion, and in 
this aspect it appears to have achieved its aim within 
the inevitable confines of a total study population of 
18 patients. However, the authors then state that there 
is no significant difference in clinical success "due to 
small numbers", and that to prove such a difference 
would require unachievable numbers of patients. 
Whilst we sympathise with the logistics of such a 
proposition, we must emphasise that we do not have 
any evidence in terms of safety, overall clinical efficacy 
or long term benefit favouring pulse-spray or even 
high dose bolus over conventional lysis techniques. 
We agree that a more rapid time to lysis is desirable 
for the acutely ischaemic limb with marked neu- 
rosensory deficit, but the vast majority of limbs can 
survive receiving thrombolysis via a conventional 
regime with corrective interventional or surgical tech- 
niques as required. 
D.C. Berridge and D. Kessel 
Leeds, U.K. 
Authors Reply 
Sir, 
Messrs. Berridge and Kessel argue that there is no 
advantage in achieving a reduction in the duration of 
thrombolytic therapy. However, they fail to support 
this with any evidence. Conventional thrombolysis 
using a low dose thrombolytic agent requires 24-48 h 
of treatment during which time monitoring on a high 
dependency or intensive care unit is required. In 
addition, out of hours angiography and maintenance 
of optimum catheter position is required. By contrast, 
thrombolytic therapy can be completed within a few 
hours in most cases with Pulse-Spray thrombolysis 
(PST). It is difficult to underestimate the potential 
advantages of this difference. Moreover, contrary to 
their experience, we still encounter many patients 
with severely ischaemic limbs who are deemed 
unsuitable for a prolonged trial of conventional 
thrombolytic therapy. 
The aim of our randomised study was to assess the 
difference in duration of lysis and not the clinical 
outcome. The sample size was more than adequate for 
this purpose. However, as pointed out in our paper 
the number of patients required to demonstrate a 
significant difference in clinical outcome is beyond the 
scope of any single centre. Even an organisation as 
large as the Thrombolysis Study Group has not been 
able to address this issue in a multi-centre study. The 
trend in thrombolytic therapy in the U.K. has there- 
fore, inevitably followed results of non-randomised 
studies. Historical controls have been used to assess 
the results of new agents and techniques. The wide 
spread shift in the choice of thrombolytic agent from 
Streptokinase to tissue plasminogen activator (rt-PA) 
for instance was led by the improved results observed 
with rt-PA in comparison to previous experience with 
Streptokinase. 1 Our results with Pulse-Spray throm- 
bolysis in 100 consecutive cases are superior to the 
previous experience with conventional thrombolysis 
in our unit. The success rate at 30 day being 70% with 
PST compared to 58% with rt-PA and 41% with 
Streptokinase using conventional lysis. 2 
S.W. Yusuf and M.E Armon 
Nottingham, U.K. 
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